Replimune Group, Inc. — Director's Dealing 2021

Jul 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2021-06-28

Reporting Person: Coffin Robert (Director, President & Chief R&D Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-28	Common Stock	S	14663	$40.04	Disposed	1806320	Direct
2021-06-29	Common Stock	S	22826	$40.05	Disposed	1783494	Direct

Footnotes

F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.15. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.21. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,783,494 shares of the Issuer's common stock. The reporting person also holds options to acquire 1,092,899 shares of the Issuer's common stock, 635,306 of which are exercisable as of the date hereof.